CHROMADEX CORP (CDXC)

ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023

CDXC stock results show that ChromaDex beat on revenue for the fourth quarter of 2023.

CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ChromaDex (NASDAQ:CDXC) just reported results for the fourth quarter of 2023.Th...

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

/PRNewswire/ -- Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just...

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

ChromaDex to Participate in the LD Micro Invitational XIII

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

ChromaDex Corporation Reports First Quarter 2023 Financial Results

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results